Lycia seeks IPO for antibody degraders as TRexBio, Retension set terms
Lycia Therapeutics, a protein degradation startup built around science out of the lab of Nobel laureate Carolyn Bertozzi, has filed for an initial public offering. Two other biotech companies are also advancing their own Nasdaq ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.